CliffBio

Biogen

Patent cliffs & loss of exclusivity

A biotechnology company with a focus on treatments for neurological and neurodegenerative diseases. It was founded in 1978 and has headquarters in Cambridge, Massachusetts.

Company

Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/biogen-idec
Facebook URLhttps://www.facebook.com/biogenjapan
Full Address225 Binney Street Cambridge, MA 02142, USA
Instagram URLhttps://www.instagram.com/biogenjapan
Legal Entity IdentifierW8J5WZB5IY3K0NDQT671
LinkedIn URLhttp://linkedin.com/company/biogen-
Pitchbook URLhttps://pitchbook.com/profiles/company/10553-05

9 upcoming patent cliffs

DrugIngredientTypeCliff
  1. SPINRAZANUSINERSEN SODIUMSmall mol.Dec 2030
  2. SPINRAZANUSINERSEN SODIUMSmall mol.Dec 2030
  3. VUMERITYDIROXIMEL FUMARATESmall mol.Oct 2033
  4. TECFIDERADIMETHYL FUMARATESmall mol.Nov 2035
  5. TECFIDERADIMETHYL FUMARATESmall mol.Nov 2035
  6. SPINRAZANUSINERSEN SODIUMSmall mol.Mar 2036
  7. ZURZUVAEZURANOLONESmall mol.Aug 2037
  8. ZURZUVAEZURANOLONESmall mol.Aug 2037
  9. ZURZUVAEZURANOLONESmall mol.Aug 2037
  10. Avonexinterferon beta-1aBiologic—
  11. Avonexinterferon beta-1aBiologic—
  12. TysabrinatalizumabBiologic—
  13. Plegridypeginterferon beta-1aBiologic—
  14. Plegridypeginterferon beta-1aBiologic—
  15. Plegridypeginterferon beta-1aBiologic—
  16. Plegridypeginterferon beta-1aBiologic—
  17. Plegridypeginterferon beta-1aBiologic—
  18. Plegridypeginterferon beta-1aBiologic—
  19. Aduhelmaducanumab-avwaBiologic—
  20. Aduhelmaducanumab-avwaBiologic—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.